JP2023551519A5 - - Google Patents

Info

Publication number
JP2023551519A5
JP2023551519A5 JP2023532759A JP2023532759A JP2023551519A5 JP 2023551519 A5 JP2023551519 A5 JP 2023551519A5 JP 2023532759 A JP2023532759 A JP 2023532759A JP 2023532759 A JP2023532759 A JP 2023532759A JP 2023551519 A5 JP2023551519 A5 JP 2023551519A5
Authority
JP
Japan
Prior art keywords
pharmaceutical product
product according
days
seq
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023532759A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023551519A (ja
Filing date
Publication date
Priority claimed from PCT/US2021/012982 external-priority patent/WO2022115120A1/en
Application filed filed Critical
Priority claimed from PCT/US2021/061145 external-priority patent/WO2022115762A1/en
Publication of JP2023551519A publication Critical patent/JP2023551519A/ja
Publication of JP2023551519A5 publication Critical patent/JP2023551519A5/ja
Pending legal-status Critical Current

Links

JP2023532759A 2020-11-30 2021-11-30 抗cd19抗体とパルサクリシブの組み合わせ療法 Pending JP2023551519A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063119370P 2020-11-30 2020-11-30
US63/119,370 2020-11-30
PCT/US2021/012982 WO2022115120A1 (en) 2020-11-30 2021-01-11 Combination therapy with an anti-cd19 antibody and parsaclisib
USPCT/US2021/012982 2021-01-11
PCT/US2021/061145 WO2022115762A1 (en) 2020-11-30 2021-11-30 Combination therapy with an anti-cd19 antibody and parsaclisib

Publications (2)

Publication Number Publication Date
JP2023551519A JP2023551519A (ja) 2023-12-08
JP2023551519A5 true JP2023551519A5 (https=) 2024-11-29

Family

ID=79021728

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023532759A Pending JP2023551519A (ja) 2020-11-30 2021-11-30 抗cd19抗体とパルサクリシブの組み合わせ療法

Country Status (6)

Country Link
US (2) US20220241411A1 (https=)
EP (1) EP4251138A1 (https=)
JP (1) JP2023551519A (https=)
CA (1) CA3203587A1 (https=)
TW (1) TW202241436A (https=)
WO (1) WO2022115762A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2767063C2 (ru) 2015-08-21 2022-03-16 МорфоСис АГ Комбинации и их использование

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5156840A (en) 1982-03-09 1992-10-20 Cytogen Corporation Amine-containing porphyrin derivatives
US5057313A (en) 1986-02-25 1991-10-15 The Center For Molecular Medicine And Immunology Diagnostic and therapeutic antibody conjugates
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
ES2176484T3 (es) 1995-08-18 2002-12-01 Morphosys Ag Bancos de proteinas/(poli)peptidos.
KR100786927B1 (ko) 2000-06-28 2007-12-17 스미스클라인비이참피이엘시이 습식 분쇄방법
CA2512729C (en) 2003-01-09 2014-09-16 Macrogenics, Inc. Identification and engineering of antibodies with variant fc regions and methods of using same
WO2004065416A2 (en) 2003-01-16 2004-08-05 Genentech, Inc. Synthetic antibody phage libraries
WO2004072266A2 (en) 2003-02-13 2004-08-26 Kalobios Inc. Antibody affinity engineering by serial epitope-guided complementarity replacement
PL2383297T3 (pl) 2006-08-14 2013-06-28 Xencor Inc Zoptymalizowane przeciwciała ukierunkowane na CD19
PT3513793T (pt) 2011-09-02 2021-05-10 Incyte Holdings Corp Heterociclilaminas como inibidores de pi3k
TWI687220B (zh) 2013-03-01 2020-03-11 美商英塞特控股公司 吡唑并嘧啶衍生物治療PI3Kδ相關病症之用途
SG10201907576SA (en) 2015-02-27 2019-09-27 Incyte Corp Salts of pi3k inhibitor and processes for their preparation
LT3302550T (lt) * 2015-05-26 2019-11-11 Morphosys Ag Anti-cd19 antikūno ir brutono tirozino kinazės inhibitoriaus derinys ir jo naudojimas
RU2767063C2 (ru) * 2015-08-21 2022-03-16 МорфоСис АГ Комбинации и их использование
LT3630177T (lt) * 2017-05-31 2023-10-25 Morphosys Ag Gydymo paradigma, skirta kompleksiniam gydymui anti-cd19 antikūnu ir venetoklaksu

Similar Documents

Publication Publication Date Title
JP2023551559A5 (https=)
JP2023524149A5 (https=)
JP2023542290A5 (https=)
JP2020503260A5 (https=)
JP2023542289A5 (https=)
JP2006522830A5 (https=)
JP2017514795A5 (https=)
JP2023541860A5 (https=)
JP2014533279A5 (https=)
JP2020525411A5 (https=)
JP2014114288A5 (https=)
JP2023541858A5 (https=)
JP2020524670A5 (https=)
JP2019517540A5 (https=)
JP2020523384A5 (https=)
JP2022512851A5 (https=)
JP2024543147A5 (https=)
JP2019532970A5 (https=)
JP2023520771A5 (https=)
JP2024069230A5 (https=)
JP2023510199A5 (https=)
JP2025512785A5 (https=)
JP2019524820A5 (https=)
JP2024540226A5 (https=)
JP2025500411A5 (https=)